Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Sep 19, 2017
| Rachel Schwartz
New Report Indicates Revising CMS Policy on Biosimilars Could Save $11.4 Billion On Medicines Over 10 Years
Press Release
Sep 19, 2017
| Rachel Schwartz
AAM and Sister Associations in Canada and Mexico: Governments Should Not Raise Drug Prices in Renegotiated NAFTA
Press Release
Sep 19, 2017
| Rachel Schwartz
CPI Penalty on Medicaid Generic Drugs Threatens Patient Access to Affordable Medicine
Report
Sep 18, 2017
| Erica Klinger
Bates-White Report: CPI-Based Medicaid Rebates Harm Generic Competition
Blog
Sep 7, 2017
| Michael Brzica
Support the CREATES Act and Help Patients Win
Video
Sep 7, 2017
| Erica Klinger
CREATES ACT - It's Time to Level the Playing Field
Infographic
Sep 6, 2017
| Erica Klinger
CREATES Act - It's Time to Level the Playing Field (Infographic)
Blog
Sep 6, 2017
| Erica Klinger
Take Action on SB 17 to Protect Patient Access and Savings for Californians
Amicus Brief
Sep 5, 2017
| Erica Klinger
AMGEN INC., AMGEN MANUFACTURING LIMITED v. SANDOZ INC.
Blog
Aug 23, 2017
| Christine Simmon
Five Reasons Why It’s Time to Lead on Biosimilars
Report
Aug 22, 2017
| Erica Klinger
Poll Results: California Proposed Drug Pricing Law (SB 17)
Press Release
Aug 22, 2017
| Erica Klinger
Poll: Majority of Californians are Unwilling to Support Proposed Drug Pricing Law
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action